# Synosis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synosis-therapeutics

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.synosia.com
- Total disclosed funding: $82M
- Latest round: Series C (Oct 12, 2010)
- Investors on record: 8

## About

Synosis Therapeutics Inc. is a biotechnology company dedicated to developing innovative therapies for neurological and psychiatric disorders, focusing on novel drug candidates and advancing clinical research to improve patient outcomes.Synosis Therapeutics Inc. specializes in developing treatments for neurological and psychiatric disorders. The company is headquartered in Basel, Switzerland. Founded by a team of experienced professionals in the biopharmaceutical industry, Synosis has undergone strategic pivots to focus on drug discovery. The most recent significant event was the acquisition by Biotie Therapies Corp. on January 11, 2011, for USD 121.5 mn, marking a pivotal change in its operational direction. The total number of deals associated with the company is five.Synosia.com primarily focuses on offering premium domain names and associated branding services tailored for startups and established businesses seeking a distinctive online presence. Their core offerings include a marketplace of over 300,000 expert-curated, brandable domains with modern extensions such as .ai, .io, and .xyz. In addition to domain sales, Synosia provides a suite of services aimed at enhancing brand identity, including naming contests that connect businesses with experts who generate unique name ideas, logo design services facilitated by AI technology, and trademark validation and filing assistance. Their clientele spans various industries, including technology, design, and fashion, and the products are marketed primarily to global audiences, with particular emphasis on regions such as North America, Europe, and Asia-Pacific. Synosia's innovative approach to branding and domain acquisition positions them as a valuable resource for companies looking to establish a memorable and impactful digital footprint.Synosia's revenue model is structured around direct transactions for domain name purchases and associated services, including branding and trademark assistance. Customers typically engage in one-time purchases of domain names, with prices starting at USD 595 for the domain Synosia.com. In addition to direct sales, the company may generate revenue through managed naming contests and logo design services, which facilitate collaborations between clients and creative professionals. The transactional structure is primarily B2B, serving a diverse client base that includes tech startups, design agencies, and other creative ventures. By offering payment plans for domain acquisitions, Synosia enables clients to manage their costs effectively while providing access to high-value assets upfront. Overall, their multifaceted offerings and transactional strategies contribute to a robust revenue generation framework that aligns with the needs of their customer segments.Synosia Therapeutics Inc. is exploring the development of new therapies targeting specific neurological disorders, with potential product launches anticipated in the coming years. The company plans to expand its reach into emerging markets in Asia-Pacific and Latin America by 2025. Recent funding from Biotie Therapies Corp. will be utilized to support these initiatives and enhance research capabilities, facilitating the advancement of their drug candidates and speeding up the delivery of innovative solutions to patients.

## Funding rounds

- Series C, Oct 12, 2010, $30M — Versant Ventures, Aravis, 5AM Ventures, Patricia Industries, UCB S.A., The Swiss Helvetia Fund Inc., Novo Holdings A/S
- Series B, Jan 7, 2009, $29M — Abingworth, Versant Ventures, Aravis, 5AM Ventures, Patricia Industries, The Swiss Helvetia Fund Inc., Novo Holdings A/S
- Series A, Dec 14, 2006, $20M — Abingworth, Versant Ventures, 5AM Ventures, Novo Holdings A/S
- Series A, Feb 16, 2006, $2.5M — Abingworth, Versant Ventures, 5AM Ventures

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B, Series C
- Novo Holdings A/S — Series A, Series B, Series C
- Aravis (https://capitalatlas.ai/funds/aravis) — Series B, Series C
- Patricia Industries (https://capitalatlas.ai/funds/patricia-industries) — Series B, Series C
- The Swiss Helvetia Fund Inc. — Series B, Series C
- UCB S.A. — Series C